Corcept Therapeutics Incorporated (CORT)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 161,493 | 124,557 | 116,191 | 125,006 | 131,602 |
| Revenue | US$ in thousands | 675,040 | 482,375 | 401,858 | 365,978 | 353,874 |
| Pretax margin | 23.92% | 25.82% | 28.91% | 34.16% | 37.19% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $161,493K ÷ $675,040K
= 23.92%
Corcept Therapeutics Incorporated's pretax margin has shown a declining trend over the five-year period from 2020 to 2024. Starting at 37.19% in December 31, 2020, the pretax margin decreased to 34.16% by December 31, 2021, and continued to decline to 28.91% by December 31, 2022. Subsequently, the pretax margin further dropped to 25.82% by December 31, 2023, and declined to 23.92% by December 31, 2024.
This downward trend in pretax margin indicates that the company's profitability before taxes has been decreasing over the years, which may raise concerns among investors and stakeholders. It suggests that Corcept Therapeutics Incorporated may be facing challenges in efficiently managing its operating expenses relative to its revenue generation. Further analysis and actions may be warranted to improve the company's profitability and overall financial performance.
Peer comparison
Dec 31, 2024